166196-73-2

Basic information

• Product Name: 2-(1H-pyrazol-5-yl)thiazole
• Synonyms: 2-(1H-pyrazol-5-yl)thiazole;2-(1H-Pyrazol-3-yl)thiazole
• CAS NO: 166196-73-2
• Molecular Formula: C₆H₅N₃S
• Molecular Weight: 151.189
• Mol File: 166196-73-2.mol

Chemical Properties

• Melting Point: 154～156℃
• Boiling Point: 385.7°C at 760 mmHg
• Flash Point: 195.9°C
• Appearance: /
• Density: 1.387g/cm³
• Vapor Pressure: 8.29E-06mmHg at 25°C
• Refractive Index: 1.652
• CAS DataBase Reference: 2-(1H-pyrazol-5-yl)thiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1H-pyrazol-5-yl)thiazole(166196-73-2)
• EPA Substance Registry System: 2-(1H-pyrazol-5-yl)thiazole(166196-73-2)

Safety Data

• Hazardous Substances Data: 166196-73-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(1H-pyrazol-5-yl)thiazole is used as a key intermediate in the synthesis of pharmaceutical compounds for its potential to contribute to the development of new drugs. Its presence in the molecular structure can influence the pharmacological properties of the final product, enhancing efficacy and selectivity.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(1H-pyrazol-5-yl)thiazole is utilized as a building block for the creation of novel agrochemicals. Its incorporation into the molecular frameworks of these products can lead to improved performance in terms of pest control and crop protection.
Used in Medicinal Chemistry Research:
2-(1H-pyrazol-5-yl)thiazole serves as a valuable compound in medicinal chemistry research, where it is explored for its potential biological activities. Researchers use 2-(1H-pyrazol-5-yl)thiazole to investigate its interactions with biological targets, which may lead to the discovery of new therapeutic agents.
Used in Drug Discovery:
As a component in drug discovery processes, 2-(1H-pyrazol-5-yl)thiazole is employed to construct and optimize drug candidates. Its unique structural features can be leveraged to improve drug-like properties, such as solubility, stability, and bioavailability, contributing to the advancement of potential new medicines.

InChI:InChI=1/C6H5N3S/c1-2-8-9-5(1)6-7-3-4-10-6/h1-4H,(H,8,9)

Upstream product

• 191729-27-8 3-(dimethylamino)-1-(thiazol-2-yl)prop-2-en-1-one 
• 24295-03-2 2-Acetylthiazole 
• 912848-91-0 3-dimethylamino-1-(2-thiazolyl)-2-propen-1-one 
• 344241-92-5 N,N-dimethylformamide dimethyl acetal 

Downstream Products

• 1345118-91-3 N-[5-(1-methyl-3-(1,3-thiazol-2-yl)pyrazol-5-yl)(2-pyridyl)](2,6-difluorophenyl)carboxamide 
• 1361379-54-5 (2,6-difluorophenyl)[5-(1-methyl-3-(1,3-thiazol-2-yl)pyrazol-5-yl)(2-thienyl)]carboxamide 
• 1599475-00-9 N-(2,6-difluorophenyl)-5-(1-methyl-3-(thiazol-2-yl)-1H-pyrazol-5-yl)thiophene-2-carboxamide 
• 1599475-01-0 N-(2,4-difluorophenyl)-5-(1-methyl-3-(thiazol-2-yl)-1H-pyrazol-5-yl)thiophene-2-carboxamide 
• 1599475-02-1 5-(1-methyl-3-(thiazol-2-yl)-1H-pyrazol-5-yl)-N-(2,4,6-trifluorophenyl)thiophene-2-carboxamide 
• 1599475-03-2 N-(2,6-difluorophenyl)-5-(1-ethyl-3-(thiazol-2-yl)-1H-pyrazol-5-yl)thiophene-2-carboxamide 
• 1599475-04-3 5-(1-ethyl-3-(thiazol-2-yl)-1H-pyrazol-5-yl)-N-(2,4,6-trifluorophenyl)thiophene-2-carboxamide 
• 1599475-11-2 2,6-difluoro-N-(5-(3-(thiazol-2-yl)-1-vinyl-1H-pyrazol-5-yl)thiophen-2-yl)benzamide 

Relevant articles and documents

PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE

The present invention provides compounds having a structure according to Formula (I) or a salt or solvate thereof, wherein ring A, X, R1, R2, R3, R4, R5 and R6, are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.

Identification of a manufacturing route of novel CRF-1 antagonists containing a 2,3-Dihydro-1 H-pyrrolo[2,3-b]pyridine moiety

A case study on the synthesis of novel CRF-1 antagonists containing the 2,3-dihydro-1H-pyrrolo[2,3-b]pyridine moiety is presented. The development of ever more efficient synthetic routes allowed the progression of three candidates at the same time. A manu

PROCESS FOR PREPARING BICYCLIC COMPOUNDS

The present invention relates to a novel process for preparing compounds of formula (IA), which are potent and specific antagonists of corticotropin-releasing factor (CRF) receptors, from intermediate compounds of formula (I), by a coupling reaction catal

Magnetic, spectral and structural aspects of spin transitions in iron(II) complexes of 2-(pyrazol-3-yl)pyridine and 3-(thiazol-2-yl)pyrazole

Tris(ligand)iron(II) complexes of 2-(pyrazol-3-yl)pyridine (3ppH) and 3-(thiazol-2-yl)pyrazole (3tpH) undergo temperature-induced singlet (1A1) →2 quintet (5T2) transitions. The transition in [Fe(3ppH)3] [CF3SO3]2.2H2O is continuous and centred above room temperature while that in the anhydrous triflate salt is discontinuous and is centred below room temperature. The latter transition occurs via a thermal hysteresis loop of width 12 K, Tc↓ and Tc↑ being 229 and 241 K, respectively. The displacement of the transition to lower temperature in the anhydrous salt is believed to be associated with the loss of hydrogen bonding involving the uncoordinated pyrazole >NH group and solvate water. In [Fe(3tpH)2(3tp)] [ClO4].2H2O and [Fe(3tpH)2(3tp)][BF4].2H2O (3tp is the deprotonated ligand) continuous transitions are observed, centred below room temperature. In these instances the displacement is consistent with the intrinsically weaker field of the bidentate system containing two five-membered heterocycles. Structural data were obtained for [Fe(3ppH)3] [CF3SO3]2.2H2O, [Fe(3tpH)3] [BF4]2.1 · 5H2O and [Ni(3tpH)3] [BF4]2.2(3tpH). The average metal-nitrogen distances in the complexes are 1.97, 2.18 and 2.09 A, severally. The large difference in the distances for the two iron complexes arises from the different ground states: a singlet for the 3ppH complex and a quintet for the 3tpH complex. In all three salts there is extensive hydrogen bonding involving the pyrazole >NH groups, the anions and the solvate molecules. [Fe(3ppH)3] [CF3SO3]2.2H2O: monoclinic, space group P21/c, a 12.33(1), b 24.44(1), c 12.55(1) A, β 115-27(4)°, Z 4. [Fe(3tpH)3] [BF4]2.1 · 5H2O: monoclinic, space group C 2/c, a 41.56(2), b 16.418(3), c 18.154(7) A, β 106.94(2)°, Z 8. [Ni(3tpH)3] [BF4]2.2(3tpH): P bcn, a 14.928(2), b 15.310 (3), c 17.882 (3) A, Z 4.